Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRME 
Prime Medicine, Inc. Common Stock (PRME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: PRME (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.89
1 Year Target Price $6.89
| 6 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.53% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 714.88M USD | Price to earnings Ratio - | 1Y Target Price 6.89 |
Price to earnings Ratio - | 1Y Target Price 6.89 | ||
Volume (30-day avg) 12 | Beta 2.4 | 52 Weeks Range 1.11 - 5.17 | Updated Date 09/16/2025 |
52 Weeks Range 1.11 - 5.17 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4787.18% |
Management Effectiveness
Return on Assets (TTM) -47.39% | Return on Equity (TTM) -154.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 743561171 | Price to Sales(TTM) 144.1 |
Enterprise Value 743561171 | Price to Sales(TTM) 144.1 | ||
Enterprise Value to Revenue 149.88 | Enterprise Value to EBITDA -3.1 | Shares Outstanding 178274000 | Shares Floating 58404386 |
Shares Outstanding 178274000 | Shares Floating 58404386 | ||
Percent Insiders 18.19 | Percent Institutions 44.28 |
Upturn AI SWOT
Prime Medicine, Inc. Common Stock
Company Overview
History and Background
Prime Medicine, Inc. was founded in 2020 by David Liu and Andrew Anzalone, pioneering prime editing, a next-generation gene editing technology. The company went public in October 2022. It focuses on developing potentially curative gene therapies for a wide range of diseases.
Core Business Areas
- Prime Editing Technology: Development of prime editing technology platform for correcting genetic mutations.
- Therapeutic Programs: Research and development of gene therapy programs targeting specific diseases using prime editing.
- Licensing and Partnerships: Out-licensing prime editing technology and forming partnerships with other biotechnology and pharmaceutical companies.
Leadership and Structure
Keith Gottesdiener, M.D., serves as the Chief Executive Officer. The company has a scientific advisory board comprised of leading experts in gene editing and related fields. Organizational structure includes research, development, and corporate functions.
Top Products and Market Share
Key Offerings
- Prime Editing Platform: A versatile gene editing technology designed to precisely correct genetic mutations at the source of disease. It has no current market share as it is still in development. Potential competitors include companies developing CRISPR-based therapies like CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (EDIT).
- Preclinical Therapeutic Programs: Prime Medicine's pipeline includes preclinical programs targeting various genetic diseases. Market share data is not applicable at this stage. The competitive landscape is broad, encompassing companies developing gene therapies for specific indications, like Vertex Pharmaceuticals (VRTX) for certain genetic disorders.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, driven by advances in technologies like CRISPR and prime editing. It's characterized by high levels of innovation, significant investment, and increasing regulatory scrutiny. The field is competitive, with numerous companies developing gene therapies for a wide range of diseases.
Positioning
Prime Medicine is positioned as a leader in prime editing technology, which offers potential advantages over other gene editing approaches in terms of precision and versatility. Their competitive advantage lies in the capabilities of the prime editing technology itself.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to be in the hundreds of billions of dollars. Prime Medicine is positioned to capture a portion of this market with its prime editing technology, potentially addressing diseases currently untreatable by other gene editing methods.
Upturn SWOT Analysis
Strengths
- Novel prime editing technology
- Strong intellectual property position
- Experienced leadership team
- Significant funding and partnerships
Weaknesses
- Technology is still early stage
- High research and development costs
- Reliance on prime editing success
- Limited clinical data
Opportunities
- Expanding therapeutic applications of prime editing
- Partnerships with pharmaceutical companies
- Potential for curative therapies for genetic diseases
- Growing market for gene editing technologies
Threats
- Competition from other gene editing technologies
- Regulatory hurdles for gene therapies
- Potential for off-target effects or other safety concerns
- High cost of gene therapies and reimbursement challenges
Competitors and Market Share
Key Competitors
- CRSP
- NTLA
- EDIT
Competitive Landscape
Prime Medicine has a competitive advantage due to their prime editing technology, which is more precise and versatile than other gene editing technologies. However, CRISPR-based competitors are further along in clinical development and have a larger market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent founding, but has had a substantial increase in revenue with more collaborations being established.
Future Projections: Future growth is dependent on the successful development and commercialization of prime editing-based therapies. Analyst estimates are positive, but subject to the risks inherent in drug development.
Recent Initiatives: Recent initiatives include expanding their pipeline of preclinical programs, securing partnerships with pharmaceutical companies, and advancing their prime editing technology.
Summary
Prime Medicine is a pioneering gene editing company with a promising prime editing technology. While still early-stage, it possesses a strong intellectual property position and experienced leadership. Success hinges on overcoming regulatory hurdles and safety considerations. The company faces stiff competition from CRISPR-based approaches but possesses significant long-term potential within the expanding gene therapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Prime Medicine Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prime Medicine, Inc. Common Stock
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-10-20 | CEO & Director Dr. Allan Reine M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 214 | Website https://primemedicine.com |
Full time employees 214 | Website https://primemedicine.com | ||
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.